Relmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023

Rhea-AI Summary

Relmada Therapeutics (Nasdaq: RLMD), a late-stage biotechnology firm specializing in CNS diseases, will announce its financial results for Q4 and full-year 2022 post-market on March 23, 2023. This will be followed by a corporate update conference call and webcast at 4:30 PM ET the same day. The company is advancing its lead program, REL-1017, targeting major depressive disorder as an adjunctive treatment. Forward-looking statements highlight potential risks, such as failure in clinical trial efficacy, regulatory approval challenges, and other uncertainties impacting future performance.

Positive

• Relmada's lead program, REL-1017, is in late-stage development targeting major depressive disorder.
• The company is also advancing a clinical-stage program in neurodegenerative diseases.

Negative

• Potential failure of trial results to demonstrate clinically significant efficacy and safety.
• Risks related to obtaining regulatory approval for REL-1017.

CORAL GABLES, Fla., March 17, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2022 after the market close on Thursday, March 23, 2023. The company will host a corporate update conference call and live audio webcast at 4:30 p.m. Eastern Time on Thursday, March 23, 2023.

Live Conference Call & Webcast:
Toll Free:	877-407-0792
International:	201-689-8263
Conference ID:	13735262
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1591728&tp_key=cb7f04a9a4

A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules. Learn more at www.relmada.com.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of Reliance trial results to demonstrate clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact:
Tim McCarthy
LifeSci Advisors
Tim@LifeSciAdvisors.com

Media Inquiries:
FischTank PR
Relmada@FischTankPR.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/relmada-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-and-webcast-on-march-23-2023-301774784.html

SOURCE Relmada Therapeutics, Inc.

FAQ

When will Relmada Therapeutics report its financial results for Q4 2022?

Relmada Therapeutics will report its Q4 2022 financial results on March 23, 2023.

What time is the Relmada Therapeutics conference call?

The conference call is scheduled for 4:30 PM ET on March 23, 2023.

What is REL-1017 in relation to Relmada Therapeutics?

REL-1017 is Relmada's lead program, a new chemical entity targeting major depressive disorder.

What are the risks associated with Relmada's forward-looking statements?

Risks include potential failures in clinical trials and challenges in obtaining regulatory approval.